Manila Times Business
POP Biotechnologies Secures Up to $9.7 Million in CEPI Funding
Funding to Propel POP BIO SNAP™ Nanoparticle Vaccine Platform into Phase 1 Clinical Trials in the U.S. Buffalo, NY, June 03, 2026 (GLOBE NEWSWIRE) -- POP Biotechnologies, Inc. ("POP BIO”), a Buffalo-based biotechnology company developing next-generation vaccines and therapeutics using proprietary porphyrin-phospholipid liposome technologies, announces that the Coalition for Epidemic Preparedness Innovations ("CEPI”) will provide up to US $9.7 million in additional funding to advance the POP BIO
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Israel, Lebanon agree to conditional ceasefire
2h ago
Quantinuum Announces Pricing of Upsized Initial Public Offering
2h ago
Origin Energy and Landis+Gyr bring large-scale smart gas technology to Australian homes and businesses
2h ago
Compal and Datasection Advance AI Infrastructure for the Production Era
2h ago